safety

January 17, 2018January 17, 2018

Health Canada Issues Safety Warning on Pulmonary Fibrosis Therapy Ofev

Reports of liver injuries stemming from the pulmonary fibrosis therapy Ofev (nintedanib), including a fatality, have prompted Health Canada to issue a safety warning about it to medical professionals. The regulatory agency said ... Read more

July 24, 2017July 24, 2017

Real-world Safety of Ofev and Esbriet Matches Trial Reports, Despite Office Patients Older, Sicker

Idiopathic Pulmonary Fibrosis, News

Patients treated with Ofev (nintedanib) or Esbriet (pirfenidone) for pulmonary fibrosis in a real-world setting have similar rates of side effects as those reported in clinical trials testing the drugs, despite ... Read more

April 28, 2017April 28, 2017

Phase 1 Interim Trial Results of miRagen’s Anti-Fibrotic Therapy Show Potential

Idiopathic Pulmonary Fibrosis, News

Initial results from a Phase 1 study on miRagen Therapeutics‘ investigative drug MRG-201 on healthy volunteers show potential for fibrous scar tissue in certain diseases. The company announced it will present ... Read more

February 15, 2017February 15, 2017

EMA Reviewing Safety of Uptravi After 5 Deaths Reported in PAH Patients in France

News, Pulmonary Hypertension

The European Medicines Agency (EMA) is re-examining the safety of Uptravi (selexipag) after five pulmonary arterial hypertension (PAH) patients in France died while taking the medicine, the agency announced in a ... Read more

September 21, 2016September 21, 2016

New Data Supports Esbriet as Safe, Effective Treatment for IPF Patients

Idiopathic Pulmonary Fibrosis, News

Positive results from four analyses based on clinical trials developed by Roche to evaluate the effectiveness of Esbriet (pirfenidone), an oral antifibrotic medication approved by the U.S. Food and Drug ... Read more

July 14, 2016July 14, 2016

E-Cigarettes Are Not Good Option for Smokers Looking to Quit, Scientists Say in Opinion Piece

News

Researchers at the University of North Carolina (UNC) at Chapel Hill strongly oppose suggestions that doctors should routinely recommend e-cigarettes as an alternative for their patients who smoke. Keeping in mind that ... Read more

October 5, 2015November 5, 2015

Anthera Pharmaceuticals Announces Start of Cystic Fibrosis Patient Recruitment For SOLUTION Clinical Trial

Cystic Fibrosis, News

Anthera Pharmaceuticals, Inc. announced that it is actively recruiting participants for its new Phase 3 clinical study on Cystic Fibrosis, called SOLUTION (Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin). ... Read more